Vaxcyte (PCVX) Change in Acquisitions & Divestments (2021 - 2026)

Vaxcyte (PCVX) has 6 years of Change in Acquisitions & Divestments data on record, last reported at $24.9 million in Q1 2026.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 94.33% to $24.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$238.9 million, a 147.87% decrease, with the full-year FY2025 number at $174.7 million, up 160.89% from a year prior.
  • Change in Acquisitions & Divestments reached $24.9 million in Q1 2026 per PCVX's latest filing, down from $68.2 million in the prior quarter.
  • Over the last five years, Change in Acquisitions & Divestments for PCVX hit a ceiling of $853.8 million in Q3 2024 and a floor of -$802.7 million in Q4 2024.
  • A 5-year average of $61.6 million and a median of $24.9 million in 2026 define the central range for Change in Acquisitions & Divestments.
  • On a YoY basis, Change in Acquisitions & Divestments climbed as much as 13298.57% in 2024 and fell as far as 233.1% in 2024.
  • Tracing PCVX's Change in Acquisitions & Divestments over 5 years: stood at $158.2 million in 2022, then skyrocketed by 281.24% to $603.1 million in 2023, then crashed by 233.1% to -$802.7 million in 2024, then skyrocketed by 108.5% to $68.2 million in 2025, then tumbled by 63.53% to $24.9 million in 2026.
  • Business Quant data shows Change in Acquisitions & Divestments for PCVX at $24.9 million in Q1 2026, $68.2 million in Q4 2025, and -$726.5 million in Q3 2025.